地尔硫治疗左室射血分数保留型心力衰竭的临床疗效研究

doi:10.3969/j.issn.1002-1949.2019.02.013

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (481 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨地尔硫〖XCZHUO.TIF;%86%86〗治疗左室射血分数保留型心力衰竭的临床疗效。方法将左室射血分数保留型心力衰竭患者87例分为对照组和治疗组。对照组42例，给予基础抗心力衰竭治疗；治疗组47例，在基础治疗上加用地尔硫。治疗3个月后观察心功能分级（NYHA）、6 min步行距离、舒张早期二尖瓣血流速度与舒张早期二尖瓣环运动速度的比值（E/E′）、脑钠肽（BNP）水平。结果治疗组总有效率高于对照组（62.22%vs.47.62%, P<0.05），治疗组治疗后6 min步行距离明显延长(m:520. 63±62.41 vs. 223.64±23.47），E/E′(8.28±4.92 vs. 10.28±5.21)及BNP水平(pg/mL:223.64±23.47 vs.170.36±21.39)明显下降，均优于对照组（P<0.05）。结论地尔硫能够改善左室射血分数保留型心力衰竭患者的心功能和临床症状。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李斌
	康爱玲
	沈洁
	陈德昌

关键词 ：左室射血分数保留, 心力衰竭, 地尔硫

基金资助:上海市卫生和计划生育委员会科研课题（20134375）

通讯作者: 陈德昌（1963-），男，主任医师，教授，博士生导师，E-mail:18918520002@189.cn。

作者简介: 李斌（1967-），男，副主任医师，E-mail:18930862828@126.com。

引用本文:

李斌，康爱玲，沈洁，陈德昌. 地尔硫治疗左室射血分数保留型心力衰竭的临床疗效研究[J]. 中国急救医学, 2019, 39(2): 161-164.
Li Bin, Kang Ai-ling, Shen Jie, Chen De-chang. Assessment of diltiazem in heart failure with preserved left ventricular ejection fraction patients. Chinese Journal of Critical Care Medicine, 2019, 39(2): 161-164.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2019.02.013 或 http://www.cnemergency.org.cn/CN/Y2019/V39/I2/161

［1］Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survivalof patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient date meta-analysis［J］. Eur Heart J, 2012, 33(14) : 1750-1757. ［2］中华医学会心脏病学分会.中国心力衰竭诊断及治疗指南［J］.中华心血管病杂志， 2014， 44（5）：1-5．［3］Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators［J］. JAMA, 1993, 270(14):1702-1707. ［4］Hillis GS, Mller JE, Pellikka PA, et al. Noninvasive estimation of left ventricular filling pressure by E/e′ is a powerful predictor of survival after acute myocardial infarction［J］. J Am Coll Cardiol, 2004, 43(3):360-367. ［5］Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy［J］. Circulation, 1999, 99(2):254-261. ［6］Ommen SR,Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures:A comparative simultaneous Doppler-catheterization study［J］. Circulation, 2000, 102 (15):1788-1794. ［7］Borlaug BA, Paulus WJ.Heart failure with preserved ejection fraction: pathophysiology，diagnosis， and treatment［J］. Eur Heart J, 2011, 32(6) : 670-679． ［8］Asrar ul Haq M, Wong C,Mutha V, et al. Therapeutic interventions for heart failure with preserved ejection fraction: a summary of current evidence［J］. World J Cardiol, 2014, 6(2) : 67-76． ［9］Bergstrm A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolicfunction.Results of the Swedish Doppler-echocardiographic study (SWEDIC)［J］. Eur J Heart Fail, 2004, 6(4) : 453-461．［10］Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction［J］. Am J Cardiol, 2004, 94(4) : 448-453． ［11］叶炳华，李爱云，朱晓燕.卡维地洛治疗舒张性心力衰竭临床观察［J］.中国心血管病研究杂志， 2005， 3(11) : 842-844. ［12］Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)［J］. Eur J Heart Fail， 2013， 15(1) : 110-118. ［13］Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction［J］. N Engl J Med, 2008, 359(23):2456-2467. ［14］van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) ［J］. J Am Coll Cardiol, 2009, 53(23): 2150-2158. ［15］Conraads VM, Metra M, Kamp O, et al.Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity,and left ventricular function of patients with diastolic dysfunction:results of the ELANDD study［J］. Eur J Heart Fail, 2012, 14(2): 219-225.